The purpose of this study is to assess the effects of hepatic impairment on the multiple dose pharmacokinetics of BMS-650032.

Inclusion Criteria:

• Male and female subjects aged 18 to 70, with hepatic impairment conforming to Child-Pugh class A,B or C
• Each matched control subjects determined to be healthy

Exclusion Criteria:

• History of esophageal and gastric bleeding within the past 6 months
• Primarily cholestatic liver disease
• Active alcoholic hepatitis
• Stable encephalopathy of ≥Stage 2
• Presence of severe ascites or edema
• Presence of hepatopulmonary or hepatorenal syndrome
• Positive for HIV
• Positive for HCV, unless HCV RNA is undetectable